Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Specialized Stem Cells Demonstrate Efficacy for Graft versus Host Disease Therapy

By BiotechDaily International staff writers
Posted on 15 Oct 2013
Image: Pluristem PLacental eXpanded (PLX) cell bioreactor (Photo courtesy of Pluristem Therapeutics).
Image: Pluristem PLacental eXpanded (PLX) cell bioreactor (Photo courtesy of Pluristem Therapeutics).
In a preclinical study, specially grown and expanded stem cells demonstrated efficacy for the treatment of Graft versus Host Disease (GvHD) following bone marrow transplantation in mice. A clinical path is now being investigated.

The study was performed using “PLacental eXpanded” (PLX) cells from Pluristem Therapeutics Inc. (Haifa, Israel), a developer of cell-based therapies by expanding noncontroversial placental-derived mesenchymal stem cells via a proprietary 3D micro-environmental process, named PluriX, into therapeutics for a variety of disorders. PLX cells provide a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. They require no tissue matching prior to administration, and thereby addressing part of the global shortfall of matched tissue for bone marrow transplantation (BMT).

In the study conducted at the Department of Bone Marrow Transplantation of the Hebrew University, Hadassah Medical Center (Jerusalem, Israel), mice underwent total body irradiation and after 24 hours received a semi-allogeneic BMT. PLX cells, or the same volumes of the control vehicle, were then injected IV (intravenous) or IM (intramuscular) into the mice concurrently with the BMT (day 0, about 20 hours after irradiation) and 5 days postirradiation. PLX markedly reduced the GvHD score, comprised of weight loss, diarrhea, skin and fur integrity, and survival. This significant (p < 0.05) improvement in the GvHD score occurred in both the IV and IM treatment groups 42 days after transplantation. Moreover, histological examination of the liver revealed reduced hepatic lymphocyte infiltration (a marker for the severity of GvHD) occurring in the PLX-treated groups, also without preference to administration route (IV or IM).

“Based on the results of this preclinical study suggesting our PLX cells may be effective in GvHD, we are pleased with the interest of leading medical institutions to use our PLX cells and will consider a cooperation to advance into a clinical program for this indication,” said Zami Aberman, Chairman and CEO of Pluristem; “[...] this study also gives Pluristem another data point demonstrating PLX cells do not have to be given intravenously to obtain a systemic effect.” This study marks the second time that IM administration of PLX cells has demonstrated a systemic effect with efficacy in a hematological disease and the fourth time when preclinical animal models for other indications are included. Systemic, beneficial effects were also noted in three patients given (under compassionate use) PLX cells IM for bone marrow failure.

Related Links:

Pluristem Therapeutics
Hebrew University – Hadassah Medical Center



Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.